Cunha K S G, Barboza E P, Da Fonseca E C
Federal Fluminense University, Medicine School, Pathology Department, Niterói, Rio de Janeiro, Brazil.
J Clin Pathol. 2003 Oct;56(10):758-63. doi: 10.1136/jcp.56.10.758.
The hallmark of neurofibromatosis type 1 (NF1) is the development of multiple neurofibromas. Solitary neurofibroma may occur in an individual who does not have NF1, but multiple neurofibromas tend to develop only in those with NF1. It has been suggested that hormones may influence the neurofibromas of patients with NF1. The evidence that hormones may influence the growth of neurofibromas comes mainly from the observation that localised neurofibromas of patients with NF1 commonly grow during puberty and pregnancy. Because growth hormone (GH) concentrations increase during puberty, it is possible that GH influences the growth of these tumours.
To investigate the presence of GH receptors (GHRs) in neurofibromas.
By means of immunohistochemistry, the presence of GHRs was investigated in two groups of patients: 16 patients without NF1 with solitary neurofibromas (group A) and 10 patients with NF1 with localised neurofibromas (group B).
Six of the 16 patients in group A had neurofibromas that were immunopositive for GHR, whereas nine of the 10 patients in group B were immunopositive.
Most patients with NF1 have localised neurofibromas that express GHR. This suggests that GH may play some role in the development of localised neurofibromas in patients with NF1.
1型神经纤维瘤病(NF1)的标志是多发性神经纤维瘤的发生。孤立性神经纤维瘤可能出现在没有NF1的个体中,但多发性神经纤维瘤往往仅在患有NF1的患者中发生。有人提出激素可能影响NF1患者的神经纤维瘤。激素可能影响神经纤维瘤生长的证据主要来自于观察到NF1患者的局限性神经纤维瘤在青春期和怀孕期间通常会生长。由于青春期生长激素(GH)浓度会升高,因此GH有可能影响这些肿瘤的生长。
研究神经纤维瘤中生长激素受体(GHR)的存在情况。
通过免疫组织化学方法,在两组患者中研究GHR的存在情况:16例无NF1的孤立性神经纤维瘤患者(A组)和10例有NF1的局限性神经纤维瘤患者(B组)。
A组16例患者中有6例神经纤维瘤GHR免疫阳性,而B组10例患者中有9例免疫阳性。
大多数NF1患者的局限性神经纤维瘤表达GHR。这表明GH可能在NF1患者局限性神经纤维瘤的发生中起一定作用。